microdose oral glp 1 Microdosing Compounded Semaglutide Noom expands its GLP-1 range

Annals of Pharmacotherapy

Novo Nordisk's semaglutide beats its counterpart liraglutide to become the next generation of weight loss innovation, and then Eli Lilly's GLP-1R/GIPR dual-target agonist tirzepatide achieves a 22.5% weight loss, surpassing semaglutide's weight loss history

GLP-1 RA-MWL leads to AT depletion, with associated skin laxity, volume loss, and accelerated aging, particularly in periorbital and midfacial regions

These sources may market retatrutide alongside FDA-approved compounds like semaglutide and tirzepatide, sometimes implying a level of pharmaceutical oversight that does not actually exist for retatrutide as an investigational compound